Literature DB >> 9449260

Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

C Peña1, M Pujol, C Ardanuy, A Ricart, R Pallares, J Liñares, J Ariza, F Gudiol.   

Abstract

An outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-KP) was detected from May 1993 to June 1995. A total of 145 patients, particularly patients in intensive care units (ICUs) (107 patients [72%]), were colonized or infected. Infection developed in 92 (63%) patients, and primary bacteremia caused by ESBL-KP was the most frequent infection (40 of 92 patients [43%]). A single clone of ESBL-KP was identified by pulsed-field gel electrophoresis analysis throughout the whole period, and no molecular epidemiological relationship could be found between the epidemic strain and non-ESBL-KP isolates. To determine risk factors for ESBL-KP infection weekly rectal swabs were obtained in three serial incidence surveys (470 patients); the probabilities of carriage of ESBL-KP in the digestive tract were 33% (October and November 1993), 40% (May and June 1994), and 0% (October and November 1995) at 10 days of ICU admission. A logistic regression model identified prior carriage of ESBL-KP in the digestive tract (odds ratio, 3.4; 95% confidence interval 1.1 to 10.4) as an independent variable associated with ESBL-KP infection. A statistically significant correlation was observed between the restricted use of oxyimino-beta-lactams (189 defined daily doses [DDD]/ 1,000 patient-days to 24 DDD/1,000 patient-days) and the trends of ESBL-KP infection (r = 0.7; P = 0.03).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449260      PMCID: PMC105455     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 4.  Epidemiology of Klebsiella and hospital-associated infections.

Authors:  J Z Montgomerie
Journal:  Rev Infect Dis       Date:  1979 Sep-Oct

Review 5.  Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance?

Authors:  J E McGowan
Journal:  Infect Control Hosp Epidemiol       Date:  1994-07       Impact factor: 3.254

6.  A new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella pneumoniae strains involved in nosocomial infections.

Authors:  P Di Martino; V Livrelli; D Sirot; B Joly; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

7.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

8.  Spread of Klebsiella pneumoniae producing SHV-5 beta-lactamase among hospitalized patients.

Authors:  A Bauernfeind; E Rosenthal; E Eberlein; M Holley; S Schweighart
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

9.  Control of aminoglycoside resistance by barrier precautions.

Authors:  R P Gaynes; R A Weinstein; J Smith; M Carman; S A Kabins
Journal:  Infect Control       Date:  1983 Jul-Aug

10.  Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 beta-lactamase and which were isolated in 14 French hospitals.

Authors:  G Arlet; M Rouveau; I Casin; P J Bouvet; P H Lagrange; A Philippon
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more
  65 in total

1.  Molecular epidemiology of a cluster of cases due to Klebsiella pneumoniae producing SHV-5 extended-spectrum beta-lactamase in the premature intensive care unit of a Hungarian hospital.

Authors:  D Szabó; Z Filetóth; J Szentandrássy; M Némedi; E Tóth; C Jeney; G Kispál; F Rozgonyi
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  Rationing antibiotic use in neonatal units.

Authors:  D Isaacs
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

3.  Outbreak of infection with extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Mexican hospital.

Authors:  J Silva; R Gatica; C Aguilar; Z Becerra; U Garza-Ramos; M Velázquez; G Miranda; B Leaños; F Solórzano; G Echániz
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae.

Authors:  J Kamile Rasheed; Gregory J Anderson; Anne Marie Queenan; James W Biddle; Antonio Oliver; George A Jacoby; Karen Bush; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital.

Authors:  Guadalupe Miranda; Natividad Castro; Blanca Leaños; Adriana Valenzuela; Ulises Garza-Ramos; Teresa Rojas; Fortino Solórzano; Lilia Chihu; Jesús Silva
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

7.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

Review 8.  Preventing the spread of multidrug-resistant gram-negative pathogens: recommendations of an expert panel of the German Society For Hygiene and Microbiology.

Authors:  Frauke Mattner; Franz-C Bange; Elisabeth Meyer; Harald Seifert; Thomas A Wichelhaus; Iris F Chaberny
Journal:  Dtsch Arztebl Int       Date:  2012-01-20       Impact factor: 5.594

Review 9.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 10.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.